Lasa Supergenerics Ltd (LASA)

Currency in INR
10.04
-0.21(-2.05%)
Closed·

LASA Financial Summary

Key Ratios

P/E Ratio-4.42
Price/Book0.78
Debt / Equity2.54%
Return on Equity-16.36%
Dividend Yield0.00%
EBITDA112.78M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Earnings

Latest Release
May 26, 2025
EPS / Forecast
-3.20 / --
Revenue / Forecast
441.50M / --
EPS Revisions
Last 90 days

FAQ

What were Lasa Supergenerics's earnings for the latest quarter?

The Lasa Supergenerics EPS (TTM) is -2.95. Lasa Supergenerics reported sales of 391.38, net income of -142.91, and EPS of -3.20 for the latest quarter.

What was Lasa Supergenerics's net income for the latest quarter?

Lasa Supergenerics's net income for the latest quarter was -142.91.

How did Lasa Supergenerics's performance compare year-over-year in the latest quarter?

The company's revenue moved from 330.80 in the previous quarter to 391.38 in the latest quarter, and net income moved from 54.94 to -142.91 compared to the previous quarter.

What is Lasa Supergenerics's net profit margin on a TTM basis?

Lasa Supergenerics's trailing twelve months (TTM) net profit margin is -10.01%.

How does Lasa Supergenerics's debt to equity ratio compare to industry standards?

Lasa Supergenerics's total debt-to-equity ratio is 2.54%.

What is Lasa Supergenerics's return on investment on a TTM basis?

Lasa Supergenerics's trailing twelve months (TTM) return on investment (ROI) is -16.36%.

What were Lasa Supergenerics's total assets and liabilities in the latest quarter?

As of the latest quarter, Lasa Supergenerics reported total assets of 1,015.32 million and total liabilities of 171.55 million.

How has Lasa Supergenerics's total revenue grown this year?

Lasa Supergenerics's total revenue was 330.80 in the previous quarter and 391.38 in the latest quarter.

What is Lasa Supergenerics's gross margin on a TTM basis?

Lasa Supergenerics's trailing twelve months (TTM) gross margin is 27.99%.

What was Lasa Supergenerics's revenue per share for the latest quarter?

Lasa Supergenerics's revenue per share for the latest quarter was 298.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.